



DIALYSIS OUTCOMES AND
PRACTICE PATTERNS STUDY

**Update from the DOPPS Program:
Improving care, outcomes, and the patient
experience**

**EDTNA Congress 2018
Genoa, Italy**

Chairpersons:

Anna Marti Monros and Loreto Gesualdo

The DOPPS Program

- The mission of the DOPPS Program is to improve the experience of patients with kidney disease by identifying links between international variations in clinical practices and outcomes.
- The studies within the DOPPS Program are designed to identify best practices for treating patients.
- Started as a hemodialysis study in 1996, the DOPPS has tracked **over 120,000 patients** on hemodialysis (**DOPPS**), peritoneal dialysis (**PDOPPS**), and with chronic kidney disease (**CKDopps**), in over 20 countries.
- By observing patients over time, and correlating practices and outcomes in different medical settings around the world, the DOPPS helps researchers identify practices and other modifiable characteristics that improve patient lives.
- Coordinated by the Arbor Research Collaborative for Health (Ann Arbor, MI USA)

Acknowledgements – 2018

The DOPPS Program would not be possible without the support for independent scientific research to improve patient care from the following organizations:

- Amgen
- AstraZeneca Pharmaceuticals LP
- Baxter Healthcare Corp
- European Renal Association-European Dialysis & Transplant Association (ERA-EDTA)
- FibroGen Inc.
- Fresenius Medical Care Asia-Pacific Ltd
- Fresenius Medical Care Canada Inc
- German Society of Nephrology (Deutsche Gesellschaft für Nephrologie - DGfN)
- Italian Society of Nephrology (SIN)
- Janssen Pharmaceuticals Inc
- Japanese Society for Peritoneal Dialysis (JSPD)
- Keryx Biopharmaceuticals, Inc
- Kidney Care UK
- Kyowa Hakko Kirin Co., Ltd
- MEDICE Arzneimittel Pütter GmbH & Co KG
- Otsuka America Pharmaceutical, Inc
- Proteon Therapeutics, Inc
- The Association of German Nephrology Centres (Verband Deutsche Nierenzentren e.V.)
- Vifor-Fresenius Medical Care Renal Pharma Ltd

Public Funding In:

Australia, Belgium, Canada, France, Thailand, United Kingdom, United States

All support for the DOPPS Program is provided without restrictions on publications.

Acknowledgements

- **We wish to thank the DOPPS study coordinators and medical directors for their dedication and hard work, and we are grateful to the patients who completed patient questionnaires**
- **A special thank you to the DOPPS CRAs for their role in supporting the study, including close communication with the participating study sites**

Agenda

1. **DOPPS: Key hemodialysis practice changes and their impact**

Loreto Gesualdo

2. **PDOPPS: New insights into optimal PD practice**

Jen King

3. **CKDopps: Opportunities to improve care now for patients with advanced CKD**

Solene Laville

4. **Empowering patients: Understanding and improving patient-provider connections**

Marisa Pegoraro

5. **Panel Discussion**